IBI303 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
271Ankylosing spondylitis1

271. Ankylosing spondylitis


Clinical trials : 574 Drugs : 359 - (DrugBank : 68) / Drug target genes : 41 - Drug target pathways : 146
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02893254
(ClinicalTrials.gov)
September 22, 201629/8/2016Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing SpondylitisA Multicenter, Randomized, Double-blind, Parallel-controlled Phase 3 Study Evaluating the Efficacy and Safety of Recombinant Human Monoclonal Antibody Against Human Tumor Necrosis Factor-a (IBI303) Compared to Adalimumab in Patients With Active Ankylosing SpondylitisASDrug: IBI303;Drug: AdalimumabInnovent Biologics (Suzhou) Co. Ltd.NULLCompleted18 Years65 YearsAll438Phase 3NULL